

NC- MEDI-CAPS LIMITED

Regd. Office & Works :
Mhow-Neemuch Road, Sector-1,
Pithampur- 454 775, Distt. Dhar,
Madhya Pradesh, INDIA

CIN : L24232MP1983PLC002231

Phone : + 91-7292-424242
Fax. : + 91-7292-407387
E-mail : info@medicaps.com
sales@medicaps.com
investors@medicaps.com
Website : www.medicaps.com

MCL/BM/SE/2018-19

7th February, 2019

Online filing at: www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Ltd.
P.J. Tower, Dalal Street, Fort
MUMBAI - 400001

BSE CODE: 523144

Sub: Submission of Standalone Un-Audited Financial Results along with Limited Review Report thereon by Statutory Auditors for the Nine Months/Quarter ended on 31st December, 2018 in accordance with Regulation 33 of the SEBI (LODR) Regulations, 2015.

Dear Sir/Madam,
This is in continuation of our letter no. MCL/BM/SE/2018-19 dated 24th January, 2019 regarding intimation of holding 04/2018-19 Meeting of the Board of Directors on Thursday, 7th February, 2019 at 3:00 P.M. for consideration and approval of the Standalone Unaudited Financial Results of the Company for the Nine Months/Quarter ended on 31st December, 2018.

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are pleased to submit the Standalone Unaudited Financial Results along with Limited Review Report thereon by Statutory Auditors for the Nine Month/Quarter ended on 31st December, 2018, in searchable PDF Format, which were also approved by the Audit Committee and Board of Directors at their meeting held on Thursday, 07th February, 2019.

Since the Limited Review Report is self-explanatory and has no modification/qualification, it needs no comments.

We are also in the process of filing the aforesaid Unaudited Financial Results in XBRL Format within the stipulated time and same shall be hosted on the website of the Company. The enclosed results will also be published in Hindi (Vernacular) & English newspaper. You are requested to please take on record the aforesaid documents for reference and further needful.

Thanking You,
Yours Faithfully,
For, **MEDI-CAPS LTD.**

AYUSHI SLOOT
COMPANY SECRETARY &
COMPLIANCE OFFICER

Encl.: Unaudited Financial Results & Limited Review Report



Indore Office :

201, Pushpratna Paradise, 9/5, New Palasia, Indore 452 001 (INDIA)

Telefax No. : +91-731-4046321, 4041435, 4028148

**LIMITED REVIEW REPORT ON UNAUDITED STANDALONE
QUARTERLY FINANCIAL RESULTS OF MEDI-CAPS LIMITED**

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED

1. We have reviewed the accompanying Unaudited Standalone Financial Results of **MEDI-CAPS LIMITED** ("the Company"), for the Quarter ended Dec 31, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim financial reporting "IND AS 34" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

2. We conducted our review of the statement in accordance with the Standard on review engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore
Date: 06/02/2019

For: Rawka & Associates
(Chartered Accountants)



A handwritten signature in blue ink, appearing to read "Venus Rawka".

Venus Rawka
(Partner)
M. No. 429040
F. R. No. 021606C

MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.),
Tel: 07292-424242, Fax: 07292-407387

Website: www.medicaps.com Email: investors@medicaps.com CIN: L24232MP1983PLC002231

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2018

(Rs. In Lakhs except EPS)

Sr. No.	Particulars	3 Months ended on			9 Months ended on		Previous Year ended on
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Income from operations						
	(a) Net sales	573.92	570.67	593.57	1632.81	1704.59	2235.35
	(b) Other operating income	22.25	17.69	14.12	52.18	37.37	65.74
	Total income from operation	596.17	588.36	607.69	1684.99	1741.96	2301.09
II	Other Income	23.29	2.23	0.00	26.01	(0.02)	1.55
III	Total Income (I+II)	619.46	590.60	607.69	1711.00	1741.94	2302.65
IV	Expenses						
	a) Cost of material consumed	311.17	234.95	211.22	784.27	630.81	879.10
	b) Purchase of stock in trade	0.00	0.00	0.09	10.73	10.41	10.41
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(10.50)	47.47	83.39	(14.72)	203.06	128.04
	d) Employee benefits expense	126.72	124.39	106.31	378.57	352.27	505.16
	e) Finance costs	0.33	0.35	0.00	1.07	0.00	0.00
	f) Power Cost	86.16	87.27	93.40	259.29	259.97	344.02
	g) Depreciation and amortization expense	8.67	8.67	16.24	26.01	48.74	33.87
	h) Other expenses	58.84	76.02	79.99	205.75	189.29	325.67
	Total Expenses	581.39	579.12	590.65	1650.97	1694.56	2226.28
V	Profit / (Loss) before exceptional items & tax (III-IV)	38.07	11.48	17.04	60.02	47.38	76.37
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit / (Loss) before tax (V-VI)	38.07	11.48	17.04	60.02	47.38	76.37
VIII	Tax Expenses						
	a) Current Tax	3.00	4.00	4.00	10.00	12.00	18.00
	b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	2.02
	Total Tax Expenses	3.00	4.00	4.00	10.00	12.00	20.02
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	35.07	7.48	13.04	50.02	35.38	56.35



X	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit/(loss) for the period (IX+XII)	35.07	7.48	13.04	50.02	35.38	56.35
XIV	Other comprehensive income						
	(a) (i) items that will not be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will not to be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	35.07	7.48	13.04	50.02	35.38	56.35
XVI	Paid-up equity share capital of the company (Face value Rs.10/- Per Share)	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
XVII	Reserves excluding revaluation reserves	0	0	0	0	0	5444.66
XVIII	Earnings per equity share (for continuing operation)						
	a) Basic	0.28	0.06	0.10	0.40	0.28	0.45
	a) Diluted	0.28	0.06	0.10	0.40	0.28	0.45
XIX	Earnings per equity share (for discontinued operation)						
	a) Basic	0	0	0	0	0	0
	a) Diluted	0	0	0	0	0	0
XX	Earnings per equity share (for discontinued and continuing operation)						
	a) Basic	0.28	0.06	0.10	0.40	0.28	0.45
	a) Diluted	0.28	0.06	0.10	0.40	0.28	0.45





Notes:

- 1 The above results were reviewed by the Audit Committee and then approved by the Board at their respective meeting held on 07.02.2019.
- 2 The statutory auditors of the company have carried out limited review of the unaudited results for the quarter ended 31.12.2018.
- 3 The Company adopted Indian Accounting Standard ("Ind AS") from 01.04.2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under.
- 4 The financial results for the quarter ended 31.12.2018 have not been reviewed by the Statutory auditors. However, the management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of the Company's affairs.
- 5 The Company is primarily engaged in manufacturing of empty hard gelatin capsules and other activities revolving around the same.
- 6 As such there is no separate reportable operating segment as defined by Ind AS -108 - " Operating Segments".
- 7 Previous quarter's figures have been regrouped/reclassified where necessary
- 8 Implementation of GST (as per the Company)
- 9 Effective 1st April, 2018, the company has adopted Ind AS 115 'Revenue from contracts with customers'. Based on the assessment done by the management, there is no material impact on the revenue recognized during the period.

Place : PITHAMPUR

Date : 07/02/2019


For MEDI-CAPS LIMITED

ALOK K. GARG
MANAGING DIRECTOR
DIN: 00274321